Výsledky vyhledávání - "Kishore Pudota"

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Autor: Eric F Morand, David A. Isenberg, Joan T. Merrill, Cristina Vazquez-Mateo, P Chang, Amy H. Kao, Daniel J. Wallace, Kishore Pudota, Cynthia Aranow

Publikováno v: Rheumatology (Oxford, England)

Objective Low disease activity (LDA) and remission are emerging treat-to-target (T2T) endpoints in SLE. However, the rates at which these endpoints are met in patients with high disease activity (HDA) are unknown. Atacicept, which targets B lymphocyt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393407b3dc87a11efe13b88698c5b23d
http://europepmc.org/articles/PMC7516108

Zobrazit plný text záznamu

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus

Autor: David A. Isenberg, Joan T. Merrill, Aida Aydemir, Kishore Pudota, Victor Ona, Cynthia Aranow, Cristina Vazquez-Mateo, Amy H. Kao, Eric F Morand, Daniel J. Wallace

Publikováno v: Rheumatology (Oxford, England). 60(11)

Objectives Atacicept reduced SLE disease activity in the phase 2b ADDRESS II study, particularly in patients with high disease activity (HDA; SLEDAI-2K ≥10) at screening. We assessed long-term safety and efficacy of atacicept in the long-term exten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3d4c68ad42586da646cbff81761b12
https://pubmed.ncbi.nlm.nih.gov/33547784

Zobrazit plný text záznamu

209 Attainment of low disease activity and remission with atacicept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension

Autor: Daniel J. Wallace, Cynthia Aranow, P Chang, Amy H. Kao, Eric F Morand, David A. Isenberg, Kishore Pudota, Joan T. Merrill, Stephen Wax, Cristina Vazquez-Mateo

Publikováno v: Abstracts.

Background Low disease activity (LDA) and remission are important goals in the treatment of patients with SLE.1 2 Lupus Low Disease Activity State (LLDAS) is associated with reduced damage accrual,2 and has been shown to be a feasible clinical trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a8a35139c9f48bc36f14e65be506324
https://doi.org/10.1136/lupus-2019-lsm.209

Zobrazit plný text záznamu

OP0251 Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extension

Autor: Cynthia Aranow, C. Vazquez–Mateo, Kishore Pudota, Stephen Wax, Daniel J. Wallace, David A. Isenberg, Joan T. Merrill, P Chang, Amy H. Kao, Eric F Morand

Publikováno v: FRIDAY, 15 JUNE 2018.

Background Low disease activity (LDA) and remission are consummate goals of SLE treatment.1 Lupus Low Disease Activity State (LLDAS) is associated with reduced damage accrual,2 and has been shown to be a feasible clinical trial endpoint.3 In the Phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a4650599688ab4e411dcd17b9f0045b
https://doi.org/10.1136/annrheumdis-2018-eular.2618

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání